Allakos drops after early-stage results for lead asset

seekingalpha06-27

Allakos (NASDAQ:ALLK) shares dropped on Wednesday after the biotech posted data from a Phase 1 trial for AK006, its most advanced drug candidate targeted at immune-mediated diseases such as chronic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446831039?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1028830260/image_1028830260.jpg","is_english":true,"pubTime":"2024-06-27 02:34","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2446831039","market":"sh","top_or_hot":-1,"title":"Allakos drops after early-stage results for lead asset","media":"seekingalpha","content":"<div>\n<p>Allakos (NASDAQ:ALLK) shares dropped on Wednesday after the biotech posted data from a Phase 1 trial for AK006, its most advanced drug candidate targeted at immune-mediated diseases such as chronic ...</p>\n\n<a href=\"https://seekingalpha.com/news/4119707-allakos-stock-drops-data-lead-asset\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos drops after early-stage results for lead asset</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos drops after early-stage results for lead asset\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-27 02:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4119707-allakos-stock-drops-data-lead-asset><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Allakos (NASDAQ:ALLK) shares dropped on Wednesday after the biotech posted data from a Phase 1 trial for AK006, its most advanced drug candidate targeted at immune-mediated diseases such as chronic ...</p>\n\n<a href=\"https://seekingalpha.com/news/4119707-allakos-stock-drops-data-lead-asset\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALLK","symbol_name":"Allakos Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4119707-allakos-stock-drops-data-lead-asset","article_id":"2446831039","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1028830260/image_1028830260.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446831039","pubTimestamp":1719426882,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Allakos  shares dropped on Wednesday after the biotech posted data from a Phase 1 trial for AK006, its most advanced drug candidate targeted at immune-mediated diseases such as chronic spontaneous urticaria . Citing data from healthy volunteers, the San Carlos, California-based biotech said that trial subjects tolerated up to 720 mg of AK006 in single and multiple doses, indicating no serious adverse events.  There were no treatment-emergent adverse events that forced trial participants to discontinue the therapy, and there were no toxicities, the company added. Today’s data came from a study testing intravenous and subcutaneous doses of AK006 in healthy participants and CSU patients. The readout represented healthy volunteers who received intravenous AK006 or placebo. Data from CSU patients receiving the IV form of the therapy is expected later this year.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALLK":"Allakos Inc.","BK4139":"生物科技"},"translate_title":"Allakos在主要资产早期业绩公布后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLK":1},"content_text":"Allakos (NASDAQ:ALLK) shares dropped on Wednesday after the biotech posted data from a Phase 1 trial for AK006, its most advanced drug candidate targeted at immune-mediated diseases such as chronic spontaneous urticaria (CSU). Citing data from healthy volunteers, the San Carlos, California-based biotech said that trial subjects tolerated up to 720 mg of AK006 in single and multiple doses, indicating no serious adverse events.  There were no treatment-emergent adverse events that forced trial participants to discontinue the therapy, and there were no toxicities, the company added. Today’s data came from a study testing intravenous and subcutaneous doses of AK006 in healthy participants and CSU patients. The readout represented healthy volunteers who received intravenous AK006 or placebo. Data from CSU patients receiving the IV form of the therapy is expected later this year.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446831039"}